Get the Stockscreener App
4.015
2.16%
0.085
Contineum Therapeutics Inc stock is traded at $4.015, with a volume of 4,967.
It is up +2.16% in the last 24 hours and up +14.39% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$3.93
Open:
$3.97
24h Volume:
4,967
Relative Volume:
0.05
Market Cap:
$126.25M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-9.5187
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
-12.14%
1M Performance:
+14.39%
6M Performance:
-70.80%
1Y Performance:
-78.92%
1-Day Range:
$3.94
$4.05
1-Week Range:
$3.911
$4.8791
52-Week Range:
$3.35
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
4.04 | 126.25M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.76 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.41 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.73 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.35 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
Bank of America Corp DE Increases Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
13,307 Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) Acquired by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Deutsche Bank AG Purchases New Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Northern Trust Corp Increases Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics ATM - Leerink Partners
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook By Investing.com - Investing.com South Africa
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $20.00 at Morgan Stanley - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - BioSpace
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics May 2025 slides: Multiple shots on goal with 2H25 catalysts ahead - Investing.com India
Barclays PLC Buys 7,978 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Wells Fargo & Company MN Raises Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday - Defense World
(CTNM) Investment Analysis - news.stocktradersdaily.com
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Contineum Therapeutics Inc Stock (CTNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):